Algeta

Activities: Manufacturing Ingredients Research & Development

Trending Articles

  1. Partnering for success: adaptable CDMO solutions for pharma, diagnostics, and biotech When it comes to liquid formulations and freeze-drying (lyophilisation) services, choosing a contract development and manufacturing organisation (CDMO) that prioritises...
  2. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows...
  3. WHO pandemic agreement determined after three years of negotiation Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks
  4. Common reasons why field certifiers fail accreditation Biosafety cabinets are the backbone of laboratory safety; however, many facilities encounter significant obstacles when using them, such as high energy consumption,...
  5. Beyond performance: GF’s SYGEF turns 50 PVDF piping systems continue to provide trusted solutions for demanding industries

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

Related Content

Pharmaceutical

Thomas Ramdahl appointed as Managing Director of Algeta

Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development

Algeta appoints Chief Scientific Officer

Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing

Algeta opens commercial production facility for Xofigo in Norway

The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing

Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement

Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies

Norwegian cancer therapeutics developer appoints president

Jeffrey Albers takes up the role at Algeta US
Regulatory

Anticancer agent – radium-223 chloride

Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development

Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227

Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now